To validate involvement in anti‐cancer response, we focused on the highly expressed ribosomal protein RPL11 (Figure 3d), which inhibits p53–HDM2 interaction (Havel et al., 2015; Lohrum et al., 2000). Here, TP53 is linked to cancer.